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Abstract
Background: Symptoms associated with pes planovalgus or flatfeet occur frequently, even though some people with a
flatfoot deformity remain asymptomatic. Pes planovalgus is proposed to be associated with foot/ankle pain and poor
function. Concurrently, the multifactorial weakness of the tibialis posterior muscle and its tendon can lead to a flattening
of the longitudinal arch of the foot. Those affected can experience functional impairment and pain. Less severe cases at
an early stage are eligible for non-surgical treatment and foot orthoses are considered to be the first line approach.
Furthermore, strengthening of arch and ankle stabilising muscles are thought to contribute to active compensation of
the deformity leading to stress relief of soft tissue structures. There is only limited evidence concerning the numerous
therapy approaches, and so far, no data are available showing functional benefits that accompany these interventions.
Methods: After clinical diagnosis and clarification of inclusion criteria (e.g., age 40–70, current complaint of foot and
ankle pain more than three months, posterior tibial tendon dysfunction stage I & II, longitudinal arch flattening verified
by radiography), sixty participants with posterior tibial tendon dysfunction associated complaints will be included in the
study and will be randomly assigned to one of three different intervention groups: (i) foot orthoses only (FOO), (ii) foot
orthoses and eccentric exercise (FOE), or (iii) sham foot orthoses only (FOS). Participants in the FOO and FOE groups will
be allocated individualised foot orthoses, the latter combined with eccentric exercise for ankle stabilisation and
strengthening of the tibialis posterior muscle. Participants in the FOS group will be allocated sham foot orthoses only.
During the intervention period of 12 weeks, all participants will be encouraged to follow an educational program for
dosed foot load management (e.g., to stop activity if they experience increasing pain). Functional impairment will be
evaluated pre- and post-intervention by the Foot Function Index. Further outcome measures include the Pain Disability
Index, Visual Analogue Scale for pain, SF-12, kinematic data from 3D-movement analysis and neuromuscular activity
during level and downstairs walking. Measuring outcomes pre- and post-intervention will allow the calculation of
intervention effects by 3×3 Analysis of Variance (ANOVA) with repeated measures.
Discussion: The purpose of this randomised trial is to evaluate the therapeutic benefit of three different
non-surgical treatment regimens in participants with posterior tibial tendon dysfunction and accompanying pes
planovalgus. Furthermore, the analysis of changes in gait mechanics and neuromuscular control will contribute to an
enhanced understanding of functional changes and eventually optimise conservative management strategies for these
patients.
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Background
The foot deformity pes planovalgus can cause symp-
toms or complaints, and may lead to dysfunction and
functional limitation [1–3]. It can be an acquired entity
where weakness of the plantarflexors and invertors of
the foot (mainly the tibialis posterior muscle) cause a
flexible or rigid flatfoot deformity [4, 5].
The posterior tibial tendon/muscle primarily serves as
a dynamic stabiliser of the foot’s medial longitudinal
arch [6]. Excessive stress can lead to tendinopathy of the
posterior tibial tendon. This leads to posterior tibial ten-
don dysfunction (PTTD). Therefore, PTTD is most often
accompanied by pes planovalgus foot deformity. Because
of the mutual prevalence of both aspects, it is not clear
if the muscle-tendon dysfunction is a result of the foot
deformity [7, 8], or if it is causative for foot deformation
[9, 10]. There is consensus that PTTD and pes planoval-
gus are closely connected [11–15].
Patients with PTTD and concomitant pes planovalgus
report pain around the medial malleolus in the tibialis
posterior muscle and its tendon. As the condition pro-
gresses, they can exhibit plantar hyperkeratosis in the
talus area and lateral impingement at the fibula-
calcaneal transition [2, 14, 15].
PTTD can be divided into four stages according to
Johnson & Strom [2]. Stage I and II comprise a still flex-
ible foot structure, which is considered to be eligible for
non-surgical treatment. Stage III and IV contain already
rigid longitudinal arch flattening with a tear of the
spring ligament complex and talar valgus tilt in the ankle
mortise [16]. Here, active compensation is not able to
take place [17, 2].
As long as PTTD and the foot deformity demonstrate
no symptoms, treatments are basically considered un-
necessary [18]. If patients do have symptoms, however, a
variety of therapy options may be administered: foot
orthoses, ankle foot orthoses, stabilising tape, exercise
(training therapy with, for example, eccentric exercise),
pain medication and/or anti-inflammatory medication
and patient education [11, 12, 15].
Optimisation of foot loading management by means of
foot orthoses and adequate footwear is the most import-
ant aspect in therapy. Depending on the progression of
the pathology, this can be progressively managed with
over-the-counter non-individualised foot orthoses, then
with individualised foot orthoses and finally with semi-
rigid ankle foot orthoses [19]. These recommendations
are published in clinical guidelines, but few high-quality
studies have investigated their efficacy [11, 12].
Poor quality studies with a variety of uncontrolled in-
terventions (foot orthoses, ankle foot orthoses, strength-
ening exercises, custom footwear, medication, ice, mega
pulse and ultrasound – isolated or combinations) report
possible benefits, but the lack of high quality, robust evi-
dence does not allow conclusions for clinical practice [1,
20–22]. The only high-quality randomised controlled
trial in patients with PTTD (and pes planovalgus) found
that patients benefit most from a combination of foot
orthoses and exercise after a 12-week intervention
period [15].
Aside from clinical outcomes, functional impairments
and their possible changes through interventions are not
described in the literature on the basis of biomechanical
measurements. Most often, static alignment measures of
foot structure like ‘navicular drop’ as a composite for
excessive pronation and/or longitudinal arch flattening
are used to quantify flatfoot alignment [23, 24].
However, dynamic measurement is more valid because
dynamic foot motion is not strongly associated with static
alignment [23, 24]. Studies on foot kinematics between
flat-arched feet and controls shows that foot function and
arch flattening can be quantified with multi-segment foot
models during weightbearing [25, 26]. Therefore, assessing
foot structure during dynamic movement seems to be the
current consensus [26–28].
Evaluations of neuromuscular function are very rare.
A study investigating neuromuscular activity of the
tibialis posterior muscle reports enhanced activity in
flat-arched asymptomatic people during stance [29].
Tibialis posterior and peroneus longus muscle activity
with the use of foot orthoses in flat-arched people
changed [30], which is in contrast to O’Connor et al.
who report that the tibialis posterior showed (at least
in running motion) inconclusive activation patterns
and no changes between different shoe conditions [31].
Another study showed reduced peroneus, lateral and
medial gastrocnemius, and soleus muscle activity dur-
ing early stance but enhanced tibialis anterior muscle
activity in participants with asymptomatic flatfoot but
with a history of musculoskeletal pain compared to
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controls [32]. This underlines the importance of readily
available neuromuscular parameters describing gait
function [33–35].
Some recent studies present sophisticated measure-
ment approaches of dynamic foot function in pes pla-
novalgus but to the authors’ knowledge, no study to
date has evaluated dynamic foot function in patients
suffering from acute complaints. Most studies use
healthy controls or asymptomatic flatfooted subjects
[36, 23, 37]. This makes it difficult to draw clear con-
clusions with regard to patients.
The aims of this study are therefore to: (i) analyse the
efficacy of three different non-surgical therapy regi-
mens in PTTD patients, and (ii) evaluate descriptively
functional outcome with a comprehensive biomechan-
ical measurement approach to learn more about
functional changes in movement generation and its
possible plasticity throughout the intervention.
Methods
Study design
The study design is a parallel-group randomised trial
with three intervention groups receiving therapy regi-
mens aimed at symptoms associated with pes planoval-
gus (Fig. 1). There will be an intervention phase of
12 weeks, which is a common therapy window for the
associated symptoms of clinical problems like pes plano-
valgus [38]. Participants’ pain and functional impairment
perception will be measured pre- and post-intervention
(and in the middle of the intervention period). Biomech-
anical measurements (standardised laboratory study)
before and after the intervention phase will accompany
Fig. 1 Study flow chart: randomisation of patients to one of three intervention groups: foot orthoses only FOO, foot orthoses and eccentric
exercise FOE, sham foot orthoses only FOS
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the protocol to evaluate possible functional changes
induced by the therapy regimen.
Study population
A cohort of 60 participants will be recruited out of six
state-wide foot surgery centres. To be included in the
trial, participants will have to have: pes planovalgus,
accompanying PTTD, associated foot pain; and a flexible
foot structure, leading to eligibility for non-surgical
treatment. Severe cases of flatfoot deformity indicating
surgical correction (e.g., rigid foot structure and not
being able to complete the test protocol due to severe
pain or impaired physical function) will be excluded.
Specific inclusion criteria are similar to Kulig [15] and
include:
 Age: 40–70 years
 Current complaint of foot and ankle pain that has
lasted for three months or more
 Flexible pes planovalgus deformity in the clinical
assessment
 PTTD of stage I and II according to Johnson &
Strom [2]
 Pes planovalgus foot deformity with longitudinal
arch flattening verified by radiograph [39]: Lateral
view: lateral talo-first metatarsal angle ≠ 0° (break of
axis): angle >10° according to Younger et al. [39],
Anteroposterior view: anteroposterior talo-first
metatarsal angle ≠ 0° (break of axis): angle >10°
according to Younger et al. [39]
 No indication/not yet an indication for surgical
treatment of foot deformity
Exclusion criteria are again similar to Kulig [38] and
include:
 Rigid foot deformity
 PTTD of stage III and IV according to Johnson
& Strom [2]
 Cardiac, neurological, peripheral vascular, or
musculoskeletal pathology
 Acute infection or alcohol addiction limiting
participation in study protocol
 Acute use of local or systemic analgesics
 Acute physical therapy, training therapy or
physiotherapy
 Acute overuse or traumatic injury to the lower leg
(excluding pes planovalgus associated pathology)
 Prior surgery to the lower limb
Participants will be included after clarification of inclu-
sion and exclusion criteria by a clinical examination and
after comprehensive written and oral information. All
participants will have to sign a written informed consent
in line with the Ethics Approval obtained from the Eth-
ics Commission of the Canton Berne (Approval number:
KEK-Nr. 158/12). Anthropometric data (gender, age,
height, weight, shoe size and foot length) will be re-
corded according to guidelines of ‘Good Clinical Prac-
tice’ in subject specific Case Report Forms [40]. All
subsequent data acquisition will also be documented in
the Case Report Forms. This secures quality control of
stored data and ensures that every single data item can
be tracked down to its origin.
Randomisation
Randomisation for group allocation to Foot Orthoses
Only (FOO), Foot Orthoses with Eccentrics (FOE) or
Sham Foot Orthoses (FOS) will take place with the
online tool www.randomization.com (no blocking or
stratification will be used). The biomechanical testing
(standing, walking and walking down a stairway) will be
administered in a fixed sequence since standing posture
serves as calibration for dynamic measurements. Group
allocation will be conducted using opaque sealed enve-
lopes (i.e., concealed allocation). The allocation list will
be stored separately and measurement personnel and
data analysing personnel will not be involved in group
allocation. Medical doctors, responsible for recruitment
and checking of eligibility, will also not be involved in
group assignment.
Blinding
Blinding of the intervention to the participants is not
possible as participants will recognise the allocated ther-
apy. The study personnel will refrain from explaining
hypothetical effects of foot orthoses, eccentric exercise
or sham foot orthoses. The measurement and data ana-
lysis personnel will be blinded to group allocation during
data acquisition and data analysis. De-blinding will take
place after statistical analysis has been completed.
Procedure
After the clinical examination, participants will be for-
warded to the study centre for further anamnestic (med-
ical history) pre-tests. A 1st measurement appointment
will then be finalised. Meanwhile, fabrication of the foot
orthoses takes place. At the 1st measurement appoint-
ment, participants’ anthropometrics and static unloaded
and loaded foot posture for characterisation will be
assessed. Following this, the participants’ foot health
status (using the Function Index FFI, German Version
(or FFI-D) [41, 42]), functional impairment (using the
Pain-Disability-Index PDI [43, 44]), and current pain
perception (using a VAS [38]) will be assessed. Biomech-
anical measurements of standing posture, level walking
and walking down stairs will then be taken. After
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biomechanical testing, a re-evaluation of pain assess-
ment with a VAS will be conducted.
After the 1st measurement appointment, an interven-
tion period will follow for 12 weeks. All participants will
receive a guideline for load management during the
intervention and an activity diary with accompanying
assessments (FFI, PDI and VAS after 6 weeks). After the
12-week intervention period, a 2nd assessment of the
patient’s foot health status (FFI), functional impairment
(PDI) and current pain perception (VAS pre/post-test),
as well as the biomechanical tests will follow. If symp-
toms persist at the end of this period, participants will
be transferred to the initial foot surgery centre for
further medical assessment and possible ongoing thera-
peutic care.
Interventions
After group allocation, all participants will be provided
with instructions about their allocated interventions
(see below). All participants will receive an educational
session where they will be informed about the length of
time to resolution of symptoms (realistic anticipation of
therapy success), importance of adhering to wearing the
foot orthoses, and issues about weight control [38]. A
guideline based on the EdUReP (Education, Unloading,
Reloading, Prevention) model, which provides a frame-
work for management of tendinopathy, accompanies the
intervention phase [45].
Participants will receive one of the following therapies
according to their random allocation:
Foot Orthoses Only (FOO)
Participants in this group will receive custom-made foot
orthoses fabricated by the same orthopaedic technician
(AR, Ortho-Team AG, Bern, Switzerland). Foot orthoses
will be fabricated out of Ethylene Vinyl Acetate (EVA,
shore 40) with a thickness at the base of approximately
4 mm. The foot will be cast in a three-dimensional foam
box impression in the neutral position of the foot under
partial weightbearing [46]. This neutral position is
already a “corrected” position for patients with the men-
tioned pathology. The 3D foam box impression serves as
the basis for implementing correcting elements in the
foot orthoses via computer-aided design software
(CAD). A medial longitudinal arch is provided for arch
support and a bowl-shaped heel is integrated to promote
rear foot stability. Finally, the foot orthoses will be fabri-
cated out of an EVA block by means of computerised
numerical control technology (CNC). A dynamic bare-
foot plantar pressure distribution to evaluate dynamic
foot function during walking (foot progression angle,
forefoot abduction and medial loading) and qualitative
gait analysis will be performed to support decision mak-
ing on the amount of medial arch posting [43]. A medial
longitudinal arch support will increase pressure at the
medial plantar surface [47, 48], which might lead to
changes in afferent input triggering neuromuscular con-
trol [34]. A top layer of Alcantara will be glued on top of
each orthosis (Table 1). All participants will wear the
device throughout the 12-week intervention for a mini-
mum of 80 % of weight-bearing tasks.
Foot Orthoses and Eccentrics (FOE)
In addition to the use of the foot orthoses described
above, eccentric strengthening exercises will be pre-
scribed in this group (concentric portions are inherent,
but emphasis is put on eccentric phases). Heel lowering
movements will be performed on the edge of a stair
from a calf raised position. For correction of rearfoot
eversion a pair of socks will be squeezed between the
calcaneii below the medial malleoli (active correction of
rearfoot eversion and medial longitudinal arch flatten-
ing). This exercise will be performed twice per day with
three sets of 15 repetitions per day for 12 weeks. Calf
raises will be performed without the squeeze of the pair
of socks to reduce load in the concentric phase. The
exercise is a modified eccentric version of that pro-
posed by Yuill and MacIntire [49]. It is combined with
the loading suggestions of Alfredson for the treatment
of Achilles tendinopathy [50, 51]. Increasing load (e.g.,
additional load with back pack) will be performed
throughout the intervention as suggested by Jonsson
[52]. Participants will be instructed by an experienced
physiotherapist. They will receive an activity booklet to
record all training sessions and possible accompanying
activities. All participants will wear the foot orthoses
throughout the 12-week intervention for a minimum of
80 % of weight-bearing tasks.
Foot Orthoses Sham (FOS)
This group will receive individually customised (sham)
foot orthoses out of the same material described above.
The functional elements of the sham orthoses, like arch
support or a bowl-shaped heel to promote rearfoot sta-
bility, are designed to assist with blinding of patients.
The foot will also be cast in a three-dimensional foam
box impression without “correcting” to a neutral pos-
ition of the foot under partial weightbearing [46]. The
sham orthoses will not receive correcting elements via
computer-aided design software (CAD). The sham foot
orthoses will also fabricated out of an EVA block by
means of computerised numerical control (CNC) tech-
nology. Like the other orthoses, a layer out of Alcantara
will be glued to the top of the sham orthoses. All partici-
pants will wear the device throughout the 12-week inter-
vention for a minimum of 80 % of weight-bearing tasks.
The participants in this group will also get an activity
booklet to record possible accompanying activity.
Blasimann et al. Journal of Foot and Ankle Research  (2015) 8:37 Page 5 of 11
All three groups will receive a phone call after one,
four and eight weeks to check for compliance, uncer-
tainties and questions (Fig. 1). If necessary, monitoring
sessions for members of the FOE group with the physio-
therapist will be organised every four weeks to control
exercise execution and to implement training load
adjustments [52]. Where participants experience obvious
fitting problems, orthoses will be slightly modified as
necessary to ensure comfort and shoe fit.
Outcome measures
Foot-Function-Index (FFI)
The evaluation of therapy efficacy will be conducted
with the main outcome measure, the FFI, before and
after the intervention. It will be administered before
the biomechanical testing on the pre/post measure-
ments. The FFI is recognised as a valid and reliable tool
[53, 54]. It is also available and valid for German lan-
guage use [41]. Furthermore, it has been used already
to evaluate PTTD patients with pes planovalgus associ-
ated complaints and is considered to be an excellent
tool in this circumstance [14, 15]. The overall (i.e.,
total) FFI score will be analysed as the primary out-
come measure. The subscales of the FFI in the dimen-
sions pain, disability and activity limitation will be
analysed separately as secondary outcome measures.
Pain-Disability-Index (PDI)
The Pain-Disability-Index (PDI), used to evaluate func-
tional impairment, will also be administered pre- and
post-intervention as a secondary outcome [43, 55]. The
PDI is a seven-item inventory designed to measure the
degree to which pain interferes with function across a
range of seven daily life dimensions (family/home
responsibilities, recreation, social activity, occupation,
sexual behaviour, self-care and life support activity).
Each item ranges from 0 (no interference) to 10 (total
interference) resulting in a sum score of 0 to 70 [56, 57,
44]. It is considered reliable for the assessment of func-
tional impairment and chronic diseases especially in
musculoskeletal pathology [58, 59]. The validity in
overuse injuries has previously been proven [43, 55].
Visual Analogue Scale (VAS)
A 100 mm visual analogue scale (VAS) with the end-
points “no pain” and “worst pain possible” is adminis-
tered before and after the biomechanical assessment to
evaluate acute pain levels. It is valid and reliable in terms
of the measurement of self-reported pain intensity [60].
Biomechanical testing
Biomechanical testing will take place before and after
the intervention. All measurements will be taken with
participants barefoot in three situations (“standing”,
“level walking” and “walking downstairs”). Participants
will walk on an even walkway with embedded force
plates (AMTI® OR6, Watertown, USA) for ground con-
tact detection and ground reaction force measurements
at a self-selected speed. Ten successful walking trials will
be collected. In addition, 10 successful trials of descend-
ing from two stair steps on the embedded force plates
will be collected. This functionally relevant situation is
administered to enhance load on the foot structures in a
functionally relevant way [61, 62].
Participants will be prepared with reflective markers
at bony landmarks according to a lower body marker
set (Vicon® Plug-In-Gait lower body, Oxford, UK) to
capture the kinematics and kinetics of hip, knee and
ankle joints. A second 4-marker set based on sugges-
tions by Dicharry will be used to measure dynamic
navicular drop [23]. A static measurement will serve as
a calibration for preceding dynamic trials. The com-
parison with the static trial will allow calculation of
changes due to the additional load application during
walking and on the stairway. A 10 camera setup (Vicon
Bonita, Vicon® Motion Systems Ltd., Oxford, UK) will
be used with a sampling rate of 200 Hz.
At the same time, the tibialis anterior, peroneal and
gastrocnemius (medial and lateral head) muscles will be
prepared bilaterally for surface EMG measurements. Lo-
calisation of disposable pregelled Al/AgCl bipolar sur-
face electrodes (Ambu®, Medicotest®, DK, type N-00-S,
distance from centre to centre: 25 mm) will be carefully
determined according to Winter and Yack and the
SENIAM procedures [63, 64]: The longitudinal axes of
the electrodes shall be in line with the presumed direc-
tion of the underlying muscle fibres. Interelectrode im-
pedance shall be kept below 5 kOhms by means of
shaving, light abrasion, degreasing and disinfecting the
skin with alcohol. The EMG electrodes will be directly
connected to differential pre-amplifiers and taped to the
skin. The pre-amplified signals will then be transmitted
via shielded cables (fixed to the leg with Velcro straps
lattice bracing) to the main amplifier (PowerPack, pfi-
tec®, Endingen, DE). Signals will be 12-bit analogue/
digital-converted and stored on a personal computer.
The sampling frequency will be set at 2000 Hz.
Signal data processing of kinematic data will calculate a
representative mean stride cycle from the 10 collected tri-
als per situation and condition. The kinematic outcome
measures will be calculated with the manufacturer’s soft-
ware Vicon Nexus® (Vicon® Motion Systems Ltd., Oxford,
UK), and MatLab® (Mathworks Inc., Natick, USA) and will
then be transferred to a data spreadsheet for statistical
analysis.
Post-processing of EMG signals will include rectifica-
tion and calculation of one average stride cycle out of 10
consecutive stride cycles. The on-off pattern of muscle
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activity will then be defined above a threshold of the
resting signal plus two standard deviations. Above this
threshold the muscle will be considered “on”. “Off” is
defined after decline of the EMG signal below this
threshold. “On” and “off” will be determined automatic-
ally by customised software (LabView®-based: Software
Imago, pfitec®, Endingen, DE) and checked visually by a
person experienced in EMG data processing but blinded
to group assignment of the individual trial. This is con-
sidered to be a reasonable procedure securing both high
standardisation and validity [65]. Total time of activation
(Ttot) will then be calculated as a percentage of total
stride time. The onset of activation (Tini) and the time
of maximum activation (Tmax) will be extracted and
expressed in relation to touchdown in % of stride [66,
34, 33, 35]. Amplitudes in the gait cycle phases pre-
activation (Apre), weight acceptance (Awa), midstance
(Ams) and push-off (Apo) will be calculated according
to the phase definition by Winter [67]: Pre-activation is
defined as the period from onset of electromyographic
activity (see above) to initial touchdown. Weight accept-
ance is the period of time between initial contact and
the following 15 % of the stride period (‘early stance’).
Midstance is the period from 15 % to 40 % of stride.
Push-off is the period of time late in stance from 40 %
of stride to toe-off [67]. The mean amplitude voltage
(MAV) per gait cycle phase will be extracted and nor-
malised to the MAV of the entire stride cycle. Hence,
Apre, Awa, Ams and Apo are determined relative to the
average activity and expressed as a fraction of the aver-
age amplitude (=1.0). Data will then be transferred from
LabVIEW®-format to a data spreadsheet for plausibility
control and statistical analysis.
Signal processing personnel will be blinded to experi-
mental condition. The electronic database will then be
checked for plausibility. All measures will be checked by
range checks to estimate validity of retrieved quantities.
Apparent discordant values will be tracked back to their
origin and data analysis will be repeated. The data
spreadsheet of all manually collected data like anthropo-
metrics will be printed as a hardcopy. Missing values will
be marked, cross-checked, added or corrected if applic-
able. Random re-evaluation of original data will serve for
cross-checking of originally analysed biomechanical data.
All outcomes and quantities of kinematic and electro-
myographic measurements are shown in Table 1 (pri-
mary, secondary and tertiary outcome measures).
Data analysis
Data will be transferred from Case Report Forms to
Microsoft® Excel for Windows (current version) spread
sheets and later processed by SPSS® (current version).
Biomechanical data will be processed with the outlined
software and final quantities will also be transferred to
spreadsheets for statistical analysis.
Statistical analysis will be performed descriptively
after plausibility control. First, testing of normal distri-
bution (Shapiro-Wilk test) of data will be followed by
the calculation of mean, standard deviation and 95 %
confidence interval. Primary outcome measure (FFI
total score) at measurement points 0, week 6 and week
12 will be analysed by 3x3 Analysis of Variance
(ANOVA) with repeated measures identifying differ-
ences in the FFI across groups (FOO, FOE, FOS) and
test sessions. This also applies for the secondary out-
come measures (FFI pain subcategory, FFI disability
subcategory and FFI activity limitation subcategory).
The primary endpoint will be set at 12 weeks. Biomech-
anical data will be analysed descriptively. Pre-post com-
parisons of those tertiary outcome measures will also
be performed where indicated after descriptive analysis
by 2×2 repeated measures ANOVA (factor group and
test day).
Sample size calculation has been based on the outlined
protocol with three intervention groups and the same
primary outcome as Kulig et al. [14, 15], where a sample
size of n = 15 per group (total N = 45) was determined
based on clinical observation, attrition rate and power
analysis. Clinical observation suggested that there is
moderate to high inter-subject variability with respect to
pain, disability and function (patient’s perception). A
drop-out rate of 20 % is assumed due to a long interven-
tion period, increase or resolution of symptoms during
the intervention, or a need for surgery requiring exit
from the study. Power analysis was based on an alpha
level of 0.05 and beta of 0.8 resulting in the proposed
sample size of 45 [38].
Based on this reported sample size with the same main
outcome and design, an à priori calculation of the total
sample size was performed leading to a group sample of
n = 20 (total N = 60) according to the following assump-
tions (Software: G*Power3, [68, 69]: test family = F-tests,
statistical test = repeated measures ANOVA, effect
size = 0.2 (medium), alpha = 0.05, power = 0.82, number
of groups = 3, number of measurements = 3, correlation
among the repeated measures = 0.5, nonsphericity correc-
tion epsilon = 1 and dropouts n = 6).
Discussion
The objective of this randomised trial is the evaluation
of the therapeutic benefit of three different non-surgical
treatment regimens (foot orthoses only FOO, foot orth-
oses and eccentric exercise FOE, sham foot orthoses
FOS) in patients with pes planovalgus and accompany-
ing complaints. The clinical validity of those therapy
regimens will result in important clinical implications.
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Table 1 Outcome measures
Primary outcome measure Unit
• Foot Function Index (FFI) – total score sum score [0–230]
Secondary outcome measures Unit
• Foot Function Index (FFI) – subcategory pain sum score [0–90]
• Foot Function Index (FFI) – subcategory disability sum score [0–90]
• Foot Function Index (FFI) – subcategory activity limitation sum score [0–50]
Tertiary outcome measures Unit
Additional assessment of functional impairment and current pain perception
• Pain Disability Index Sum score [0–70]
• Visual Analog Scale (VAS) assessing pain (pre-post biomechanical testing) Score [0–10]
Tertiary outcome measures from biomechanical data Unit
Kinematic data from 3D movement analysis
Distance
• Dynamic navicular drop Millimeter [mm]
Kinematic data from 3D movement analysis
Angular data: angle at initial contact, maximal manifestation during stance, range
• Foot Progression Angle Angular degree [°]
• Forefoot to rearfoot dorsiflexion Angular degree [°]
• Forefoot to rearfoot adduction Angular degree [°]
• Forefoot to rearfoot supination Angular degree [°]
• Ankle dorsiflexion Angular degree [°]
• Ankle adduction Angular degree [°]
• Ankle eversion Angular degree [°]
(hindfoot with respect to tibia)
• Ankle dorsiflexion Angular degree [°]
• Ankle adduction Angular degree [°]
• Ankle eversion Angular degree [°]
(hindfoot with respect to lab)
• Knee flexion Angular degree [°]
• Knee adduction Angular degree [°]
• Knee internal rotation Angular degree [°]
• Hip flexion Angular degree [°]
• Hip adduction Angular degree [°]
• Hip internal rotation Angular degree [°]
Neuromuscular activity
EMG of M. tibialis anterior, M. peroneus longus, M. gastrocnemius lateralis/medialis, M. soleus
• Onset of activation % of stride
• Time of maximum activation % of stride
• Total time of activation % of stride
• Normalized amplitude in preactivation arbitrary unit [uV/uV]
• Normalized amplitude in weight acceptance arbitrary unit [uV/uV]
• Normalized amplitude in mid-stance arbitrary unit [uV/uV]
• Normalized amplitude in push-off arbitrary unit [uV/uV]
Primary, secondary and tertiary outcome measures of this RCT
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The lack of evidence for non-surgical treatment strat-
egies emphasises the need for such a trial. Beside the fact
that established clinical outcomes will be used to assess
clinical efficacy of therapy regimens, the novel aspect of
the trial is to integrate biomechanical measurements of
lower extremity and foot function.
The development and final set-up of the intervention
groups was the subject of great debate between the in-
vestigators, the funding agency’s international reviewers
and the ethics committee. The author/investigator group
initially planned foot orthoses as the basic therapy for all
three groups. The promising results of the aforemen-
tioned RCT by Kulig et al. [15] justified this approach
[38]. Consequently, according to the best available
evidence, foot orthoses were planned for all groups. One
group with additional eccentric exercises and one group
with additional “traditional” physiotherapy (a regimen of
ice, ultrasound, electrotherapy, manual therapy) were
planned to assess the additive effect of exercise therapy
and physiotherapy. The rationale for eccentric exercises
was derived from existing evidence for the treatment of
(chronic) tendinopathy [51, 50, 52]. Physiotherapy was
planned to be integrated into this trial because it reflects
current physiotherapeutic practice in the daily routine.
The reviewers of the funding agency rejected the physio-
therapy therapy modality due to lack of any scientific
evidence. During the process of ethics approval, the
regional ethics committee, acting as the legal authority
in Switzerland came to the conclusion that there is also
no rationale for foot orthoses since the trial by Kulig et
al. did not evaluate foot orthoses against a wait-and-see
approach [15]. They concluded that research ethics allow
refraining from foot orthoses in this patient group. Con-
sequently, they requested an untreated control group.
The investigator group emphasised that there are fre-
quent dropouts in such a control group and suggested a
sham orthosis group as a control. The ethics committee
finally approved this idea and the funding agency also
accepted the final therapy group definitions.
The rationale for the measurement of the gait me-
chanics and neuromuscular control in this trial is to gain
a comprehensive view on functional changes due to
pathology and their plasticity during the intervention.
One study has analysed kinematic differences between
healthy and PTTD patients in a heel rise movement
[70]. It found that stage II PTTD patients exhibited
greater plantar flexion to achieve heel rise compared to
healthy controls [70]. The same study found greater tibi-
alis posterior muscle lengthening during walking and
greater hindfoot eversion during stance [71, 72].
The tibialis posterior muscle is the main muscular
stabiliser for active longitudinal arch stabilisation [73].
Foot orthoses with an arch support have been found to
selectively activate the tibialis posterior muscle [74].
Therefore, it would be the best muscular indicator in
the context of pes planovalgus, but measurements of
this deep lower leg muscle are not possible with surface
electromyography. Accordingly, the trial refrains from
using highly invasive techniques, so as to not place
study participants at risk. There are reports of synergistic
activity of the tibialis posterior muscle and the superficially
available peroneus longus muscle [29]. The approach is,
therefore, to evaluate easily available parameters that can
be transferred to clinical settings. Further assessment of
the tibialis anterior muscle and gastrocnemius (medialis
and lateralis) muscles [66, 34, 33, 35] will be performed to
cover the “neuromuscular” dimension that relate to com-
mon kinematic movements like dynamic navicular drop,
rearfoot eversion, etc.
The analysis of possible functional changes in gait me-
chanics and neuromuscular control will contribute to an
enhanced understanding of functional changes that
occur with conservative management. This will enable
us to generate theories about the mechanisms possibly
involved in the process of symptom relief. Furthermore,
a subsequent aim is to optimise conservative manage-
ment strategies, which may lead to more efficient use of
health care resources.
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